European Medicines Association (EMA) statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC)
The European Medicines Association (EMA) issued a statement on Obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis (PBC) on 28 06 2024.
The EMA has recommended that the marketing authorisation for Ocaliva be revoked in the European Union following results of the COBALT trial, 747-302 . In the UK EMA recommendations do not apply, as we are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). At present, there are no changes to the recommendations on use of Obeticholic acid in PBC from the MHRA or the National Institute for Health and Care Excellence (NICE) and so current prescribing practices should NOT change.
We shall update the UK liver community if there are any changes to the recommendations on the use of Obeticholic acid.
Congratulations to our new Mentoring Lead, Dr Noor Jawad
We are delighted to welcome our new BSG Mentoring Lead, Dr Noor Jawad.
A career as a clinical academic in gastroenterology by Prof Alexander Ford
We’re delighted to share that Prof Alexander Ford, one of the most respected figures in gastroenterology for his prolific academic output and publishing record, has written an insightful new piece for Frontline Gastroenterology: “Reflecting on a career as a clinical academic in gastroenterology.”
.png?width=416&height=277&ext=.png)
We are introducing member voting for the next BSG President-Elect
The BSG introducing an important change to the way we select our future President. From 2026, members will have the opportunity to vote for the President-Elect as part of a new pilot election process designed to increase transparency, strengthen governance, and enhance member engagement.